Screening methods and therapeutic treatments for pigment dispersion syndrome
AssigneeThe Jackson Laboratory
InventorsMichael G. Anderson, Simon W.M. John
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Jackson Laboratory
InventorsMichael G. Anderson, Simon W.M. John
Estimating the term…
Disclosed are methods for identifying a genetic disorder associated with pigment dispersion syndrome or pigmentary glaucoma in a mammal. The methods include analytical characterization of a nucleic sample from an afflicted individual, and comparison of this characterization with an otherwise identical characterization of a nucleic acid sample from a non-afflicted individual. Also disclosed are methods for identifying a compound useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma. Such methods include the study of melanocyte cell cultures from afflicted and/or non-afflicted individuals, and the effect of test compounds on such cultures. Also disclosed are methods for identifying a therapeutic compound through the use of a mouse model system. Therapeutic methods are also encompassed within the scope of the present disclosure.
A method for identifying a genetic disorder associated with pigment dispersion syndrome or pigmentary glaucoma in a mammal, the method comprising:
A method for identifying a compound useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma, the method comprising:
A method for identifying a compound useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma, the method comprising:
A method for identifying a compound useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma, the method comprising:
A therapeutic method for treating a mammal afflicted with pigment dispersion syndrome or pigmentary glaucoma, the method comprising administering to the mammal a therapeutically effective amount of a compound which reduces melanin production in the iris.
An oligonucleotide which hybridizes specifically to a mutant form of the glycoprotein (transmembrane) nmb gene under stringent hybridization conditions, the mutant form of the glycoprotein (transmembrane) nmb gene being linked with pigment dispersion syndrome or pigmentary glaucoma.
An oligonucleotide which hybridizes specifically to a mutant form of the tyrosinase-related protein 1 gene under stringent hybridization conditions, the mutant form of the tyrosinase-related protein 1 gene being linked with pigment dispersion syndrome or pigmentary glaucoma.
Dependencies are inferred from the claim text.